Abington Neurological Associates is proud to have participated in the TRAILBLAZER-ALZ study that produced these results. We are currently conducting the phase 3 trial, TRAILBLAZER-ALZ-2.
In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer’s disease.